Perrigo Co PLC
PRGO
Company Profile
Business description
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm’s product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Contact
The Sharp Building
Hogan Place
DublinD02 TY74
IRLT: +353 17094000
E: Bradley.Joseph@perrigo.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2024
Employees
9,140
Stocks News & Analysis
stocks
Microsoft earnings: Strength in cloud, guidance mixed
We think investors should be on board when Azure accelerates in the third quarter.
stocks
Chart of the week: Small caps lagging
This week's chart of the week comes from Morningstar's Market Strategist's take on small caps
stocks
An impending merger just raised our fair value for this ASX retail giant
The deal is set to deliver enhanced scale, cost savings and new synergies.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,344.80 | 77.30 | -0.92% |
| CAC 40 | 7,350.37 | 77.99 | -1.05% |
| DAX 40 | 19,077.54 | 179.80 | -0.93% |
| Dow JONES (US) | 41,763.46 | 378.08 | -0.90% |
| FTSE 100 | 8,110.10 | 49.53 | -0.61% |
| HKSE | 20,317.33 | 63.31 | -0.31% |
| NASDAQ | 18,095.15 | 512.78 | -2.76% |
| Nikkei 225 | 39,081.25 | 196.14 | -0.50% |
| NZX 50 Index | 12,579.18 | 59.72 | -0.47% |
| S&P 500 | 5,705.45 | 108.22 | -1.86% |
| S&P/ASX 200 | 8,083.80 | 76.20 | -0.93% |
| SSE Composite Index | 3,279.82 | 13.59 | 0.42% |